Bifogade filer
PDF
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Bio-Works Technologies AB has received an order worth SEK 12 million from a global pharmaceutical company, with delivery scheduled for 2026. The order covers the product WorkBeads affimAb, used for antibody purification in commercial manufacturing processes.
The returning customer has already implemented WorkBeads affimAb in several of its commercial production lines. This new order strengthens the long-term collaboration between the companies and marks the first step toward an expanded partnership.
WorkBeads affimAb is an affinity chromatography resin designed for efficient and selective purification of antibodies, making it an attractive choice for large-scale biopharmaceutical manufacturing.
"We are very proud to receive continued trust from one of the world's leading pharmaceutical manufacturers. This order is a strong validation of our product's performance in large-scale, commercial processes - and an important step towards a deeper partnership. It reinforces our position as a strategic supplier to the global biopharmaceutical industry," says Lone Carlbom, CEO of Bio-Works Technologies AB.
This order is a further sign of Bio-Works' commercial growth and confirms the company's position as a trusted partner to the global biopharma industry.
This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on "Innehållet inom klamrarna kommer ersättas med rätt tid och datum vid utskickstillfället">14-04-2025 16:27 CET.